title: A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
abstract: A second anterior ridge formed 8 weeks after therapy in a case of zone II, stage 3 retinopathy of prematurity, which was treated with intravitreal bevacizumab injection alone. The clinical appearance was defined as "double ridge." Retinopathy of prematurity cases treated only with intravitreal bevacizumab injections may progress; therefore, close follow-up is recommended.
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Yaz
authors.forename: Nazmiye
authors.initials: N
authors.lastname: Erol
authors.forename: Huseyin
authors.initials: H
authors.lastname: Gursoy
authors.forename: Hikmet
authors.initials: H
authors.lastname: Basmak
authors.forename: Mustafa D
authors.initials: MD
authors.lastname: Bilgec
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D018450:Disease Progression; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D017075:Laser Coagulation; D012166:Retinal Hemorrhage / Q000209:etiology / Q000601:surgery; D015861:Retinal Neovascularization / Q000188:drug therapy / Q000209:etiology*; D012178:Retinopathy of Prematurity / Q000188:drug therapy / Q000209:etiology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab